@sanilrege @psycheureka 16 patients placebo, 17 received memantine. 8 week follow up. https://t.co/hQgwfQyKpj
Effect of the Glutamate NMDA Receptor Antagonist Memantine as Adjunctive Treatment in Borderline Personality Disorder: An Exploratory, Randomised, Double-Blind, Placebo-Controlled Trial. https://t.co/EKn6S9rA4D
RT @psychopharmacol: Small RCT: Memantine at a 20-mg daily dose is a well tolerated drug that can improve Borderline personality disorder s…
RT @psychopharmacol: Small RCT: Memantine at a 20-mg daily dose is a well tolerated drug that can improve Borderline personality disorder s…
Small RCT: Memantine at a 20-mg daily dose is a well tolerated drug that can improve Borderline personality disorder symptomatology compared with placebo (p = 0.02) https://t.co/iPLVm74Y2n
RT @MAPrc_WMHD: New publication from MAPrc's WMHD! @maprc1 @jayashrikulkar1 Effect of the Glutamate NMDA Receptor Antagonist Memantine as…
New publication from MAPrc's WMHD! @maprc1 @jayashrikulkar1 Effect of the Glutamate NMDA Receptor Antagonist Memantine as Adjunctive Treatment in Borderline Personality Disorder: An Exploratory, Randomised, Double-Blind, Placebo-Controlled Trial https:/